Brandywine Global Investment Management LLC Raises Stock Position in Organon & Co. (NYSE:OGN)

Brandywine Global Investment Management LLC grew its holdings in shares of Organon & Co. (NYSE:OGN) by 34.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,029,923 shares of the company’s stock after buying an additional 521,847 shares during the quarter. Brandywine Global Investment Management LLC owned 0.79% of Organon & Co. worth $30,286,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. Horizon Bancorp Inc. IN increased its stake in Organon & Co. by 2,401.5% during the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock worth $25,000 after acquiring an additional 1,585 shares during the last quarter. Millstone Evans Group LLC bought a new stake in shares of Organon & Co. in the 4th quarter valued at approximately $29,000. Larson Financial Group LLC boosted its holdings in shares of Organon & Co. by 345.4% in the 4th quarter. Larson Financial Group LLC now owns 2,236 shares of the company’s stock worth $33,000 after purchasing an additional 1,734 shares during the period. Riverview Trust Co increased its position in shares of Organon & Co. by 117.7% during the 4th quarter. Riverview Trust Co now owns 2,390 shares of the company’s stock valued at $36,000 after purchasing an additional 1,292 shares during the last quarter. Finally, Versant Capital Management Inc raised its holdings in Organon & Co. by 92.2% during the 4th quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock valued at $41,000 after buying an additional 1,324 shares during the period. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Organon & Co. Stock Performance

Shares of Organon & Co. stock opened at $14.52 on Monday. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The stock’s fifty day moving average is $15.33 and its two-hundred day moving average is $16.21. Organon & Co. has a 52 week low of $13.87 and a 52 week high of $23.10. The company has a market capitalization of $3.74 billion, a PE ratio of 4.36, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. As a group, analysts expect that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.72%. The ex-dividend date was Monday, February 24th. Organon & Co.’s payout ratio is 33.63%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. TD Cowen raised shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Morgan Stanley lowered their target price on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a report on Friday, February 14th. Finally, Barclays dropped their price target on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Organon & Co. has an average rating of “Hold” and a consensus price target of $20.80.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.